Ascentage Pharma Unveils Strong POLARIS‑1 & Lisaftoclax Data at ASH 2025
Ascentage Pharma unveils new olverembatinib and lisaftoclax data at ASH 2025, showing breakthrough advances in targeted leukemia and BCL‑2 therapies.
- Ascentage Pharma Group International
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read